Sector News

Actavis CEO Brent Saunders To Continue At Helm Upon Acquisition Of Allergan

December 16, 2014
Life sciences
(RTTNews.com) – Specialty pharmaceutical company Actavis plc Tuesday said upon the closing of the acquisition of Allergan Inc. in the second quarter next year, its CEO and President Brent Saunders will continue to lead the firm. Paul Bisaro will remain executive chairman. Members from Actavis and Allergen will constitute the senior management.
 
The company said the new leadership would capitalize on the value of Allergan’s world-renowned businesses and the proven track record of the leaders of its powerful and critically important franchises.
 
Saunders said Allergan President Douglas Ingram will continue as a Special Advisor.
 
Following the close of the acquisition, Acatavis’ global brand sales and marketing will be structured into International Brands, Branded Pharma and Allergan Medical. Paul Navarre, Allergan Corporate Vice President and President Europe, Africa and the Middle East, will be the executive vice president of Actavis, and President of International Brands. William Meury, Actavis Executive Vice President for North American Brands will become Executive Vice President Actavis, and President, Branded Pharma with responsibility for Eye Care, Neurosciences, Gastroenterology, Urology, Women’s Health and other Specialty brand portfolios. Philippe Schaison, Allergan Corporate Vice President, President Allergan Medical, will become Executive Vice President Actavis, President Allergan Medical, which will include Facial Aesthetics, Medical Dermatology, Plastic Surgery and SkinMedica. All these individuals will report directly to Saunders.
 
Actavis’David Nicholson, Senior Vice President, Global Brand R&D will be the executive vice president, Branded R&D directly reporting to Saunders.
 
Generics and Global Operations will be led by Robert Stewart, currently Actavis’ chief operating officer.
 
Further, Actavis announced the senior management team for its Global Functions, which will report to Saunders. Maria Teresa (Tessa) Hilado will serve as EVP, Chief Financial Officer for the combined company. Robert Bailey will serve as EVP, Chief Legal Officer and Corporate Secretary. Karen Ling, will serve as EVP, Chief Human Resources Officer; Charlie Mayr will serve as EVP, Chief Communications Officer; Sigurd Kirk will serve as EVP, Corporate Business Development and Jonathan Kellerman will serve as EVP and Global Chief Compliance Officer.
 
Alex Kelly, Actavis Senior Vice President and Chief Integration Officer; and Sanjiv Patel, Allergan Corporate Vice President, Global Strategic Marketing & Global Health Outcomes Strategy and Research, will share jointly in the responsibility for Pre-Integration Planning.
 
 

comments closed

Related News

September 22, 2023

Novo Holdings acquires biopharma company Paratek for $462m

Life sciences

Novo Holdings has concluded the acquisition of all outstanding shares of commercial-stage biopharmaceutical company Paratek Pharmaceuticals for nearly $462m (€433.67m) to bolster its antimicrobial resistance (AMR) expertise. Paratek develops and commercialises new treatments for life-threatening ailments. Its speciality pharmaceutical platform aids in developing new therapeutics.

September 22, 2023

Glenmark Pharma to divest 75% stake in life sciences unit for $680m

Life sciences

Glenmark Pharmaceuticals has signed a definitive agreement for the divestiture of a 75% stake in its division, Glenmark Life Sciences (GLS), to Indian company Nirma in a deal valued at Rs56.51bn ($679.85m). Glenmark Life Sciences focuses on producing active pharmaceutical ingredients (API).

September 22, 2023

Lonza-CEO Ruffieux to leave Swiss CDMO

Life sciences

Pierre-Alain Ruffieux, CEO of Lonza, will leave the Basel-based company at the end of September. According to the Swiss Contract Development and Manufacturing Organization (CDMO), the separation is by mutual agreement.

How can we help you?

We're easy to reach